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Introduction
More than 230,000 new cases of prostate cancer were diagnosed in the United States in 2006 and more than 27,000 deaths were attributed to prostate cancer, accounting for ~9% of cancer deaths in men. It is clear that there is a need for more effective highly targeted agents for the treatment of this pervasive cancer. Our goal is to explore a novel approach, namely inhibition of a specific protein, ERG, to treat this deadly disease.
We have proposed three steps to achieve our goal of finding compounds that can inhibit ERG function by stabilizing the inhibited form of the protein. First, we will make ERG in bacteria and identify which parts of the protein mediate the inhibition. Second, we will utilize nuclear magnetic resonance spectroscopy to determine the 3D structure of the inhibited form of ERG. This structural information makes it possible to use computational tools to identify molecules which may bind to ERG. Third, we will use these computational tools to identify potential lead compounds which can stabilize the inhibited form of ERG and inhibit its binding to DNA. Based on the computational results, we will test a selected panel of compounds for their ability to inhibit binding of ERG to DNA to identify compounds which are effective and can be developed further into a useful drug.
Our efforts can lay the foundation for development of drugs targeting ERG which is a novel and potentially therapeutically powerful approach for the treatment of prostate cancer.
Body Aim 1: Delineation of auto-inhibitory domains of ERG.
Generation of constructs. Using PCR, we have generated 6 constructs in pHIS Parallel 2 thus far for expression of a series of fragments of ERG (see Table below ).
ERG1 Expression of ERG residues 1-462 (full-length) ERG2
Expression of ERG residues 211-462 ERG3 Expression of ERG residues 261-412 ERG4 Expression of ERG residues 290-412 ERG5 Expression of ERG residues 290-383 ERG6 Expression of ERG residues 290-377
Expression and purification. All six of these constructs have been expressed in E. coli using low temperature (10 ºC) induction with IPTG. The resulting protein is expressed in a soluble form. Purification is effected using Ni-NTA affinity chromatography, rTEV cleavage of the His 6 tag, and a second Ni-NTA affinity chromatography step to obtain homogeneous protein. Fluorescence polarization (FP) assay for measuring ERG-DNA binding. For the measurement of K d values for the binding of ERG fragments to DNA, we have developed a fluorescence polarization assay. Several functional DNA sequences identified from selected and amplified binding (SAAB) using the highly homologous Fli-1 protein (Mao et al., 1994) have been synthesized with a 3'-fluorescein label. Upon binding of the larger ERG protein, the fluorescence polarization is altered due to the decreased rotational correlation time of the complex, providing a simple, robust assay for these measurements (Rishi et al., 2005) . A representative binding plot for binding of ERG3 to DNA is shown in Figure 2 below. We are also measuring the K d values using isothermal titration calorimetry to provide an independent determination. This assay has been used to measure K d values for several constructs with one DNA element:
The results of these measurements clearly that longer fragments of ERG (beyond the canonical Ets domain) do indeed show evidence of auto-inhibition, validating our original aim to explore this for ERG. The data also suggest that the ERG3 construct contains most, if not all of the regions of the protein necessary for auto-inhibition so we will focus our structural efforts on this ~150 amino acid fragment. 
